Original articleOutcomes of Eyes Lost to Follow-up with Proliferative Diabetic Retinopathy That Received Panretinal Photocoagulation versus Intravitreal Anti–Vascular Endothelial Growth Factor
Abbreviations and Acronyms
Cited by (0)
Financial Disclosure(s): The author(s) have made the following disclosure(s): J.H.U.: Consultant – UCB (Brussels, Belgium); Financial support – Roche/Genentech (San Francisco, CA), Santen (Osaka, Japan), Ophthotech (New York, NY).
C.D.R.: Consultant – Genentech (San Francisco, CA), Alcon (Fort Worth, TX), Allergan (Dublin Ireland), Iconic (San Francisco, Iconic), Notal Vision (Prince William County, VA); Financial support – Roche/Genentech (San Francisco, CA), Regeneron (Tarrytown, NY), Allergan (Dublin, Ireland), Novartis (Basel, Switzerland), Iconic (San Francisco, Iconic).
J.I.M.: Consultant – Genentech (San Francisco, CA); Lecturer – Regeneron (Tarrytown, NY).
S.J.G.: Consultant – Deciphera (Waltham, MA), Santen (Osaka, Japan); Financial support – Aerpio (Cincinnati, OH), Allergan (Dublin, Ireland), Eyegate (Waltham, MA).
HUMAN SUBJECTS: Human subjects were included in this study The human ethics committees at Wills Eye Hospital approved the study. All research complied with the Health Insurance Portability and Accountability (HIPAA) Act of 1996 and adhered to the tenets of the Declaration of Helsinki. The need for informed consent was waived.
No animal subjects were included in this study.
Author Contributions:
Conception and design: Obeid, Su, Gao, Fineman, Regillo, Hsu
Analysis and interpretation: Obeid, Su, Patel, Uhr, Borkar, Gao, Fineman, Regillo, Maguire, Garg, Hsu
Data collection: Obeid, Su, Patel, Uhr, Borkar, Maguire, Garg, Hsu
Obtained funding: N/A
Overall responsibility: Obeid, Su, Patel, Uhr, Borkar, Gao, Fineman, Regillo, Maguire, Garg, Hsu